<p><em>源自美国国会正在进行的 FY27 NDAA 流程</em></p>
<p><em>优先考虑既具有预防性（放射保护剂）又具有治疗性（放射减轻剂）的辐射/核对策</em></p>
<p><em>跟随公司最近两次针对国防部高级官员的简报，介绍其针对急性辐射综合症的主要候选药物 Entolimod</em></p>
<p>, /PRNewswire/ -- Valion Bio, Inc.（纳斯达克代码：VBIO）（&#34;Valion Bio&#34;或&#34;公司&#34;）（前称 Tivic Health Systems, Inc.），一家晚期生物制药公司，今天确认美国众议院武装服务委员会（&#34;委员会&#34;）的 FY27 国家防御授权法案（&#34;NDAA&#34;）报告指示国防部核威慑、化学和生物防御政策与计划助理秘书（&#34;ASD (ND-CBD)&#34;）与国防部卫生事务助理秘书（ASD (HA)）协调，制定优先考虑既具有预防性（暴露前）又具有治疗性（暴露后）的辐射/核对策的资源和部署计划。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mmx.prnewswire.com/media/MS1837876/Valion-Logo_Logo.jpg/query-aWQ9T0EyNjk3NDgw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mmx.prnewswire.com/media/MS1837876/Valion-Logo_Logo.jpg/query-aWQ9T0EyNjk3NDgw"/></p>
<p>委员会对辐射/核对策的关注解决了一个重要的部队保护和准备挑战，强调提供既具有预防性又具有治疗效果的医疗对策。这一要求支持了一个全面的战略，以开发应对新兴威胁的可持续方法，特别是使国防部（&#34;DoW&#34;）处于应对辐射和核暴露的先进准备状态。</p>
<p>该开发紧随 Valion Bio 于 2026 年 4 月向 ASD (ND-CBD) 的简报和 2026 年 5 月向生物医学高级研究与发展局（BARDA）的简报，介绍其主要候选药物 Entolimod。</p>
<p>Entolimod 是一种重组缺失变体的沙门氏菌 FliC 鞭毛蛋白，经过工程改造以选择性激活 TLR5。接触后，Entolimod 触发特定通路，最终促进多组织细胞保护并抑制放射敏感的造血和胃肠组织中的细胞凋亡。该化合物在美国食品药品监督管理局（&#34;FDA&#34;）的动物规则下的控制非人灵长类动物研究中显示出作为放射保护剂和放射减轻剂的生存益处。</p>
<p>Valion Bio 首席执行官 Michael Handley 表示：&#34;长期以来，核/辐射准备依赖于只能在损害发生后使用的药物。我们强烈赞扬委员会认识到国家需要一种如 Entolimod 这样的辐射对策，能够在暴露前和暴露后都有效。我们感到非常振奋的是，美国国防机构的最高层现在正在优先考虑这一能力。&#34;</p>
<p><strong>关于 Valion Bio, Inc.</strong></p>
<p>Valion Bio, Inc.（纳斯达克代码：VBIO），前称 Tivic Health Systems, Inc.，正在开发激活先天免疫通路以实现细胞保护并调节在辐射、疾病和免疫失调条件下的免疫反应的生物制剂。公司的主要候选药物 Entolimod 用于急性辐射综合症（ARS），已被广泛研究，并在 FDA 的动物规则下显示出生存益处和改善组织恢复。Entolimod 是一种新型的 Toll 样受体 5（TLR5）激动剂，激活 NF-κB 信号通路以保护细胞免受损伤并刺激免疫反应。Entolimod 用于 ARS 已获得美国食品药品监督管理局的快速通道和孤儿药资格。Valion Bio 还在推进 Entolasta，这是一种下一代 TLR5 激动剂，旨在潜在地拓宽治疗应用，包括肿瘤支持治疗。Valion Bio 的全资子公司 Velocity Bioworks 是一家全方位服务的合同开发和制造组织（CDMO），为第三方生物科技公司提供生物制造服务。Valion Bio 还利用 Velocity Bioworks 的制造能力推进自己的药物管线，预计将带来降低成本、加速制造成果和供应链安全的好处。</p>
<p>欲了解更多信息，请访问 www.valionbio.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含 1995 年《私人证券诉讼改革法》所定义的&#34;前瞻性声明&#34;，包括关于 Entolimod 与国防需求潜在对齐、政府优先考虑、资金或采购的潜力，以及公司的发展计划的声明。FY27 NDAA 报告语言未提及 Valion Bio 或 Entolimod，也不构成对公司的 DoW 合同、拨款、采购、奖励或资金承诺。不能保证 Valion Bio 将获得任何政府资金、合同或采购，或 Entolimod 将被选为任何政府项目。诸如&#34;鼓励&#34;、&#34;定位&#34;、&#34;潜力&#34;和类似表达的词语标识前瞻性声明。这些声明基于当前的期望，并受到可能导致实际结果显著不同的风险和不确定性的影响，包括但不限于 FY27 NDAA 流程的不确定结果、缺乏政府资金、合同或采购的任何保证、监管审查和 FDA 动物规则下潜在批准的风险和时机，以及公司在美国证券交易委员会的文件中描述的其他风险因素，包括其 10-K 表格的年度报告和 10-Q 表格的季度报告。除法律要求外，公司没有义务更新任何前瞻性声明。</p>
<p><strong>投资者 + 媒体联系：</strong></p>
<p>Rich Cockrell</p>
<p>CG Capital</p>
<p>vbio@cg.capital</p>
<p>来源 Valion Bio, Inc.</p>

VBIO

<p>Valion Bio（纳斯达克股票代码：VBIO）确认，美国众议院武装服务委员会的 2027 财年国防授权法案报告指示国防部制定一项计划，以优先考虑具有预防和治疗效果的辐射/核对策。这一消息是在 Valion Bio 对其主要候选药物 Entolimod（用于急性辐射综合症）的简报之后发布的。该公司表示，这与国家防御需求相符，但澄清该报告并不构成合同或资金承诺</p>

<p><em>Emanates from the FY27 NDAA process underway in the U.S. Congress</em></p>
<div class="lb-trans"><p><em>源自美国国会正在进行的 FY27 NDAA 流程</em></p>
</div><p><em>Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant)</em></p>
<div class="lb-trans"><p><em>优先考虑既具有预防性（放射保护剂）又具有治疗性（放射减轻剂）的辐射/核对策</em></p>
</div><p><em>Follows Company's two recent briefings for senior DoW officials regarding its lead candidate, Entolimod, for acute radiation syndrome</em></p>
<div class="lb-trans"><p><em>跟随公司最近两次针对国防部高级官员的简报，介绍其针对急性辐射综合症的主要候选药物 Entolimod</em></p>
</div><p>, /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) (&#34;Valion Bio&#34; or the &#34;Company&#34;) (f/k/a Tivic Health Systems, Inc.), a late-stage biopharmaceutical company, confirmed today that the U.S. House Armed Services Committee's (the &#34;Committee&#34;) FY27 National Defense Authorization Act (&#34;NDAA&#34;) report directs the Assistant Secretary of Defense for Nuclear Deterrence, Chemical, and Biological Defense Policy and Programs (&#34;ASD (ND-CBD)&#34;), in coordination with the Assistant Secretary of Defense for Health Affairs (ASD (HA)), to develop a resources and fielding plan for prioritizing radiation/nuclear countermeasures that are both prophylactic (pre-exposure) and therapeutic (post-exposure).</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Valion Bio, Inc.（纳斯达克代码：VBIO）（&#34;Valion Bio&#34;或&#34;公司&#34;）（前称 Tivic Health Systems, Inc.），一家晚期生物制药公司，今天确认美国众议院武装服务委员会（&#34;委员会&#34;）的 FY27 国家防御授权法案（&#34;NDAA&#34;）报告指示国防部核威慑、化学和生物防御政策与计划助理秘书（&#34;ASD (ND-CBD)&#34;）与国防部卫生事务助理秘书（ASD (HA)）协调，制定优先考虑既具有预防性（暴露前）又具有治疗性（暴露后）的辐射/核对策的资源和部署计划。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mmx.prnewswire.com/media/MS1837876/Valion-Logo_Logo.jpg/query-aWQ9T0EyNjk3NDgw" alt="" original-src="https://mmx.prnewswire.com/media/MS1837876/Valion-Logo_Logo.jpg?id=OA2697480"/></p>
<p>The Committee's focus on radiation/nuclear countermeasures addresses an important force protection and readiness challenge by emphasizing medical countermeasures that offer both prophylactic as well as therapeutic efficacy. This requirement supports a comprehensive strategy for developing sustainable approaches to emerging threats, and, specifically, it positions the Department of War (&#34;DoW&#34;) in an advanced state of readiness and response to radiation and nuclear exposures.</p>
<div class="lb-trans"><p>委员会对辐射/核对策的关注解决了一个重要的部队保护和准备挑战，强调提供既具有预防性又具有治疗效果的医疗对策。这一要求支持了一个全面的战略，以开发应对新兴威胁的可持续方法，特别是使国防部（&#34;DoW&#34;）处于应对辐射和核暴露的先进准备状态。</p>
</div><p>The development closely follows <em>[comes on the heels of]</em> Valion Bio's April 2026 briefing to the ASD (ND-CBD) and its May 2026 briefing to the Biomedical Advanced Research and Development Authority (BARDA) about its lead candidate, Entolimod.</p>
<div class="lb-trans"><p>该开发紧随 Valion Bio 于 2026 年 4 月向 ASD (ND-CBD) 的简报和 2026 年 5 月向生物医学高级研究与发展局（BARDA）的简报，介绍其主要候选药物 Entolimod。</p>
</div><p>Entolimod is a recombinant deletion variant of Salmonella FliC flagellin engineered to activate TLR5 selectively. Upon engagement, Entolimod triggers specific pathways that ultimately promote multi-tissue cytoprotection and inhibit apoptosis in radiosensitive hematopoietic and gastrointestinal tissues. The compound has demonstrated survival benefit as both a radioprotectant and a radiomitigant in controlled non-human primate studies under the U.S. Food and Drug Administration's (&#34;FDA&#34;) Animal Rule.</p>
<div class="lb-trans"><p>Entolimod 是一种重组缺失变体的沙门氏菌 FliC 鞭毛蛋白，经过工程改造以选择性激活 TLR5。接触后，Entolimod 触发特定通路，最终促进多组织细胞保护并抑制放射敏感的造血和胃肠组织中的细胞凋亡。该化合物在美国食品药品监督管理局（&#34;FDA&#34;）的动物规则下的控制非人灵长类动物研究中显示出作为放射保护剂和放射减轻剂的生存益处。</p>
</div><p>Valion Bio CEO, Michael Handley, said , &#34;For too long, nuclear/radiation preparedness has relied on agents that can only be used after the damage is done. We strongly commend the Committee for recognizing that the nation needs a radiation countermeasure, such as Entolimod, that works both before and after exposure. And we're incredibly energized that the highest levels of the U.S. defense establishment are now prioritizing this capability.&#34;</p>
<div class="lb-trans"><p>Valion Bio 首席执行官 Michael Handley 表示：&#34;长期以来，核/辐射准备依赖于只能在损害发生后使用的药物。我们强烈赞扬委员会认识到国家需要一种如 Entolimod 这样的辐射对策，能够在暴露前和暴露后都有效。我们感到非常振奋的是，美国国防机构的最高层现在正在优先考虑这一能力。&#34;</p>
</div><p><strong>About Valion Bio, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Valion Bio, Inc.</strong></p>
</div><p>Valion Bio, Inc. (Nasdaq: VBIO), the new corporate identity of Tivic Health Systems, Inc., is developing biologics that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease, and immune dysregulation. The Company's lead candidate, Entolimod for acute radiation syndrome (ARS), has been extensively studied and has demonstrated survival benefits and improved tissue recovery in animal models under the FDA's Animal Rule. Entolimod is a novel Toll-like receptor 5 (TLR5) agonist that activates NF-κB signaling pathways to protect cells from damage and stimulate immune responses. Entolimod for ARS has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration. Valion Bio is also advancing Entolasta, a next-generation TLR5 agonist designed for potential broader therapeutic applications, including oncology supportive care. Valion Bio's wholly owned subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) that offers biomanufacturing services to third-party biotech companies. Valion Bio also leverages Velocity Bioworks' manufacturing capabilities to advance its own drug pipeline with the expected benefits of lower costs, accelerated manufacturing outcomes, and supply chain security.</p>
<div class="lb-trans"><p>Valion Bio, Inc.（纳斯达克代码：VBIO），前称 Tivic Health Systems, Inc.，正在开发激活先天免疫通路以实现细胞保护并调节在辐射、疾病和免疫失调条件下的免疫反应的生物制剂。公司的主要候选药物 Entolimod 用于急性辐射综合症（ARS），已被广泛研究，并在 FDA 的动物规则下显示出生存益处和改善组织恢复。Entolimod 是一种新型的 Toll 样受体 5（TLR5）激动剂，激活 NF-κB 信号通路以保护细胞免受损伤并刺激免疫反应。Entolimod 用于 ARS 已获得美国食品药品监督管理局的快速通道和孤儿药资格。Valion Bio 还在推进 Entolasta，这是一种下一代 TLR5 激动剂，旨在潜在地拓宽治疗应用，包括肿瘤支持治疗。Valion Bio 的全资子公司 Velocity Bioworks 是一家全方位服务的合同开发和制造组织（CDMO），为第三方生物科技公司提供生物制造服务。Valion Bio 还利用 Velocity Bioworks 的制造能力推进自己的药物管线，预计将带来降低成本、加速制造成果和供应链安全的好处。</p>
</div><p>For more information, visit www.valionbio.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.valionbio.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains &#34;forward-looking statements&#34; within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Entolimod's potential alignment with defense requirements, the potential for government prioritization, funding, or procurement, and the Company's development plans. The FY27 NDAA report language does not reference Valion Bio or Entolimod, and does not constitute a DoW contract, grant, procurement, award, or funding commitment to the Company. There can be no assurance that Valion Bio will receive any government funding, contract, or procurement, or that Entolimod will be selected for any government program. Words such as &#34;encouraged,&#34; &#34;positions,&#34; &#34;potential,&#34; and similar expressions identify forward-looking statements. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including, without limitation, the uncertain outcome of the FY27 NDAA process, the absence of any assurance of government funding, contract, or procurement, the risks and timing of regulatory review and potential approval under the FDA's Animal Rule, and the other risk factors described in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statement except as required by law.</p>
<div class="lb-trans"><p>本新闻稿包含 1995 年《私人证券诉讼改革法》所定义的&#34;前瞻性声明&#34;，包括关于 Entolimod 与国防需求潜在对齐、政府优先考虑、资金或采购的潜力，以及公司的发展计划的声明。FY27 NDAA 报告语言未提及 Valion Bio 或 Entolimod，也不构成对公司的 DoW 合同、拨款、采购、奖励或资金承诺。不能保证 Valion Bio 将获得任何政府资金、合同或采购，或 Entolimod 将被选为任何政府项目。诸如&#34;鼓励&#34;、&#34;定位&#34;、&#34;潜力&#34;和类似表达的词语标识前瞻性声明。这些声明基于当前的期望，并受到可能导致实际结果显著不同的风险和不确定性的影响，包括但不限于 FY27 NDAA 流程的不确定结果、缺乏政府资金、合同或采购的任何保证、监管审查和 FDA 动物规则下潜在批准的风险和时机，以及公司在美国证券交易委员会的文件中描述的其他风险因素，包括其 10-K 表格的年度报告和 10-Q 表格的季度报告。除法律要求外，公司没有义务更新任何前瞻性声明。</p>
</div><p><strong>Investor + Media Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者 + 媒体联系：</strong></p>
</div><p>Rich Cockrell</p>
<div class="lb-trans"><p>Rich Cockrell</p>
</div><p>CG Capital</p>
<div class="lb-trans"><p>CG Capital</p>
</div><p>vbio@cg.capital</p>
<div class="lb-trans"><p>vbio@cg.capital</p>
</div><p>SOURCE Valion Bio, Inc.</p>
<div class="lb-trans"><p>来源 Valion Bio, Inc.</p>
</div>

Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures | VBIO Stock News

Valion Bio（纳斯达克股票代码：VBIO）确认美国众议院武装服务委员会的倡议，旨在解决辐射/核反制措施的紧迫需求 | VBIO 股票新闻